Artiva Biotherapeutics (NASDAQ:ARTV) Insider Sells $63,088.02 in Stock

Posted by George Bondi on May 19th, 2026

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) insider Christopher Horan sold 7,002 shares of the company’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $63,088.02. Following the completion of the sale, the insider owned 293,450 shares of the company’s stock, valued at approximately $2,643,984.50. The trade was a 2.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ ARTV traded down $0.67 during trading on Tuesday, hitting $8.55. The stock had a trading volume of 844,679 shares, compared to its average volume of 581,930. Artiva Biotherapeutics, Inc. has a 12 month low of $1.47 and a 12 month high of $14.53. The company has a market capitalization of $211.36 million, a PE ratio of -2.42 and a beta of 2.86. The firm has a fifty day moving average of $8.32 and a two-hundred day moving average of $5.65.

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last posted its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, equities analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ARTV shares. HC Wainwright increased their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Wall Street Zen lowered shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Cantor Fitzgerald increased their price target on shares of Artiva Biotherapeutics from $10.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. Finally, Wedbush increased their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $39.00.

View Our Latest Stock Report on Artiva Biotherapeutics

Institutional Investors Weigh In On Artiva Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its holdings in Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the last quarter. Prelude Capital Management LLC purchased a new stake in Artiva Biotherapeutics during the third quarter valued at about $41,000. Dimensional Fund Advisors LP purchased a new stake in Artiva Biotherapeutics during the first quarter valued at about $131,000. OMERS ADMINISTRATION Corp purchased a new stake in Artiva Biotherapeutics during the fourth quarter valued at about $91,000. Finally, Sanctuary Advisors LLC purchased a new stake in Artiva Biotherapeutics during the first quarter valued at about $139,000.

Artiva Biotherapeutics Company Profile

(Get Free Report)

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.